In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second Genome Inc.

www.secondgenome.com

Latest From Second Genome Inc.

Interview: KoBioLabs Pioneering The Microbiome Landscape In Korea

Industry interest in the development of microbiome modulators is noticeably increasing worldwide. In South Korea, KoBioLabs is leading the charge to microbiome drug development, helped by a sizable database and biobank. Its founder and CEO GwangPyo Ko talked to Scrip about its core technology, pipeline progress, and general strategy.

South Korea Research & Development

Tech Transfer Roundup: Vanderbilt Teams With Deerfield; Expands Cancer Pact With Boehringer

Vanderbilt launches new biotech with Deerfield aimed at reworking the drug development paradigm, while also expanding its cancer research work with BI. Grunenthal partners with Katholieke Universiteit Leuven to investigate ion channel modulation approaches in pain.

Research & Development Deals

Microbiome Clinical Studies Loom Large In 2018

Events are moving fast in the microbiome field. The sector is expecting results from numerous initial clinical studies during 2018, from across a spectrum of approaches and mechanisms of action, which could lead to new rounds of financings and M&A activity.

Clinical Trials Research & Development

Second Genome CEO Predicts Paradigm Shift With Microbiome Discovery

California biotech, which has backing from major pharmas, explains the application of its microbiome discovery platform to multiple disease types.

Companies Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Alias(es)
  • PhyloTech Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Second Genome Inc.
  • Senior Management
  • Karim Dabbagh, PhD, Pres. & CEO
    Mohan S Iyer, CBO
    Brian Dowd, VP, Finance
  • Contact Info
  • Second Genome Inc.
    Phone: (650) 440-4606
    341 Allerton Ave.
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register